CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 18 enrolled
Drug / intervention
IV BCAA +2 moredietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02697305
NCT02697305N/ACompleted

Effect of Intravenously and Orally Administered Branched Chain Amino Acids on Incretin Response

Charles University, Czech Republic·interventional·Posted Mar 3, 2016·Updated Mar 8, 2016

In Brief

A clinical study evaluating IV BCAA, ORAL BCAA, and 1 other intervention for Glucose Metabolism Disorders. Completed, enrolled 18 participants across 1 site.

Detailed Summary

Branched chain amino acids (BCAA) are known to exert insulinogenic effect. Whether this effect is mediated by incretins (GLP-1, GIP) is not known. The aim of the study was to show incretin effect of BCAA, i.e. whether the oral administration of BCAA elicits higher insulin and incretin response when compared with IV route of the same dose of BCAA. Eighteen healthy, male subjects participated in three tests: IV application of BCAA solution (30.7±1.1 g of BCAA, IV BCAA) second was oral ingestion of BCAA capsules in the same dose (ORAL BCAA) and third experiment was oral placebo (PLACEBO). Glucose, insulin, GLP-1, GIP, valine, leucine and isoleucine levels were measured at time interval for up to 4 h.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesCzechia
Collaborators--

Timeline

N/ACompletedFinished
201520162017201820192020202120222023202420252026
First PostedMar 3, 2016
Enrollment StartSep 1, 2014
Primary CompletionMay 1, 2015
Study CompletionDec 1, 2015
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 10.3 years ago

Interventions

IV BCAAdietary

in total dose of 0,4 g/kg in a 2 h intravenous infusion

ORAL BCAAdietary

single dose of 0.4g/kg administered over 30s washed down with 500mL of tap water

ORAL Placeboother

single dose of 0.4 g/kg administered over 30 s washed down with 500mL of tap water